Antler joins SG healthtech startup Zeya in $575k pre-seed round
- ByStartupStory | January 13, 2026
Antler Co-Leads $575K Pre-Seed for Zeya, Singapore’s AI-Driven Chronic Care Platform
Zeya, a Singapore-based healthtech startup building AI-powered chronic disease management solutions, has raised $575,000 in pre-seed funding co-led by Antler and Java Capital, with angel participation from regional healthcare leaders.
The round gives Zeya 18-24 months runway to launch its MVP across Southeast Asia’s diabetes and hypertension markets, where 300 million+ patients struggle with medication adherence and care coordination. Backers see Zeya capturing the $15 billion regional digital therapeutics opportunity amid aging populations and rising NCD burdens.
AI Med Agents for Chronic Care Gaps
Founded in 2025 by ex-Temasek healthtech lead Dr. Mei Ling and serial entrepreneur Raj Patel, Zeya develops “MedAgents” – autonomous AI companions that orchestrate end-to-end chronic care beyond reminders. Each agent:
-
Predicts adherence risks 72 hours early using wearable vitals, pharmacy fills, and behavioral signals
-
Executes micro-interventions: Auto-refills via insurer APIs, family alerts, doctor escalations
-
Optimizes regimens: ML-driven dose timing synced to lifestyle, food intake, circadian rhythms
-
Monetizes outcomes: Risk-adjusted pricing tied to A1C reduction, BP control rates
Unlike telehealth or wearables, Zeya owns the care loop – coordinating doctors, pharmacies, insurers, and families through a clinician dashboard showing cohort-level intervention ROI.
Funds Build Clinical + Market Moats
Capital flows into three execution pillars:
Clinical Validation: Randomized trials across Singapore, Indonesia, Philippines proving 25% adherence lift, 15% ER visit reduction. Partnerships with Raffles Medical, IHH Healthcare accelerate adoption.
Regional GTM: MVP launch Q3 2026 targeting Singapore’s universal healthcare + Indonesia’s 20M diabetics. B2B2C model sells to insurers (50% margins) and employers (wellness ROI).
AI Infrastructure: Multi-lingual LLMs trained on 10M+ Asian patient journeys for culturally attuned coaching. HIPAA/PIPEDA compliance unlocks enterprise trust.
Antler Partner Sarah Chen highlighted: “Zeya scales what nurses do best – patient orchestration – through AI at 1/50th cost, solving chronic care’s biggest scalability blocker.”
SEA Healthtech’s Perfect Storm
Zeya times four convergences:
-
Universal coverage expansion: Singapore, Thailand digitize NCD programs
-
Wearable penetration: 40% smartphone users track vitals
-
Insurer mandates: 80% premiums now tie to outcomes, not volume
-
Doctor shortages: 1:2000 ratios force protocolized care delegation
Peers focus on screening; Zeya owns management – the 90% value portion of chronic care spend.
Path to Category Leadership
Pre-seed positions Zeya for $5M seed by mid-2027 after 10K patient cohorts and $2M ARR. Series A by 2028 could value at $100M+ as outcomes data creates defensible moat.
In Asia’s $200B chronic care tsunami, Zeya proves AI doesn’t replace doctors – it amplifies them, delivering population-scale prevention where humans alone can’t scale.
Follow Startup Story
Related Posts
